Codiak BioSciences is a clinical-stage biopharmaceutical company that develops exosome-based therapeutics for various diseases, including oncology, neurology, and infectious diseases. Its lead product candidates are exoSTING and exoIL-12 for the treatment of solid tumors. The company also has collaborations with several organizations and is headquartered in Cambridge, Massachusetts.